High-throughput Screening in Colorectal Cancer Tissue-originated Spheroids

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Oct 22

PMID 30343529

Citations 62

Authors

Jumpei Kondo

Tomoya Ekawa

Hiroko Endo

Kanami Yamazaki

Norio Tanaka

Yoji Kukita

Hiroaki Okuyama

Jiro Okami

Fumio Imamura

Masayuki Ohue

Kikuya Kato

Taisei Nomura

Arihiro Kohara

Seiichi Mori

Shingo Dan

Masahiro Inoue

Affiliations

Soon will be listed here.

Abstract

Patient-derived cancer organoid culture is an important live material that reflects clinical heterogeneity. However, the limited amount of organoids available for each case as well as the considerable amount of time and cost to expand in vitro makes it impractical to perform high-throughput drug screening using organoid cultures from multiple patients. Here, we report an advanced system for the high-throughput screening of 2427 drugs using the cancer tissue-originated spheroid (CTOS) method. In this system, we apply the CTOS method in an ex vivo platform from xenograft tumors, using machines to handle CTOS and reagents, and testing a CTOS reference panel of multiple CTOS lines for the hit drugs. CTOS passages in xenograft tumors resulted in minimal changes of morphological and genomic status, and xenograft tumor generation efficiently expanded the number of CTOS to evaluate multiple drugs. Our panel of colorectal cancer CTOS lines exhibited diverse sensitivities to the hit compounds, demonstrating the usefulness of this system for investigating highly heterogeneous disease.

Citing Articles

Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges.

Bandara S, Raveendran S Cancers (Basel). 2025; 17(5).

PMID: 40075668 PMC: 11899461. DOI: 10.3390/cancers17050821.

Reply to: comment on "Early cancer detection by serum biomolecular fingerprinting spectroscopy with machine learning".

Dong S, He D, Zhang Q, Huang C, Hu Z, Zhang C Light Sci Appl. 2025; 14(1):54.

PMID: 39828747 PMC: 11743758. DOI: 10.1038/s41377-024-01664-2.

Advances in the application of colorectal cancer organoids in precision medicine.

Zhang Y, Meng R, Sha D, Gao H, Wang S, Zhou J Front Oncol. 2024; 14:1506606.

PMID: 39697234 PMC: 11653019. DOI: 10.3389/fonc.2024.1506606.

Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing for Colorectal Cancer.

Randall-Demllo S, Al-Qadami G, Raposo A, Ma C, Priebe I, Hor M Cancers (Basel). 2024; 16(21).

PMID: 39518102 PMC: 11544769. DOI: 10.3390/cancers16213664.

Growth pattern of de novo small clusters of colorectal cancer is regulated by Notch signaling at detachment.

Lin Y, Coppo R, Onuma K, Endo H, Kondo J, Iwabuchi S Cancer Sci. 2024; 115(11):3648-3659.

PMID: 39300760 PMC: 11531966. DOI: 10.1111/cas.16299.

References

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D . Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83(11):757-66. DOI: 10.1093/jnci/83.11.757. View

Aberle M, Burkhart R, Tiriac H, Olde Damink S, Dejong C, Tuveson D . Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg. 2018; 105(2):e48-e60. PMC: 5774241. DOI: 10.1002/bjs.10726. View

Magi A, Tattini L, Cifola I, DAurizio R, Benelli M, Mangano E . EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol. 2013; 14(10):R120. PMC: 4053953. DOI: 10.1186/gb-2013-14-10-r120. View

Ben-David U, Ha G, Tseng Y, Greenwald N, Oh C, Shih J . Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017; 49(11):1567-1575. PMC: 5659952. DOI: 10.1038/ng.3967. View

Friedrich J, Seidel C, Ebner R, Kunz-Schughart L . Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009; 4(3):309-24. DOI: 10.1038/nprot.2008.226. View

van de Wetering M, Francies H, Francis J, Bounova G, Iorio F, Pronk A . Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4):933-45. PMC: 6428276. DOI: 10.1016/j.cell.2015.03.053. View

Nakajima A, Endo H, Okuyama H, Kiyohara Y, Kimura T, Kamiura S . Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix. Int J Cancer. 2014; 136(12):2949-60. DOI: 10.1002/ijc.29349. View

Drost J, Clevers H . Organoids in cancer research. Nat Rev Cancer. 2018; 18(7):407-418. DOI: 10.1038/s41568-018-0007-6. View

Sachs N, Clevers H . Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev. 2014; 24:68-73. DOI: 10.1016/j.gde.2013.11.012. View

10.

Horvath P, Aulner N, Bickle M, Davies A, Del Nery E, Ebner D . Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016; 15(11):751-769. DOI: 10.1038/nrd.2016.175. View

11.

Yoshida T, Okuyama H, Nakayama M, Endo H, Nonomura N, Nishimura K . High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. Cancer Sci. 2014; 106(1):69-77. PMC: 4317779. DOI: 10.1111/cas.12567. View

12.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K . Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378):920-926. PMC: 6112415. DOI: 10.1126/science.aao2774. View

13.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

14.

Yoshii Y, Furukawa T, Waki A, Okuyama H, Inoue M, Itoh M . High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment. Biomaterials. 2015; 51:278-289. DOI: 10.1016/j.biomaterials.2015.02.008. View

15.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

16.

Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y . High-throughput screening in colorectal cancer tissue-originated spheroids. Cancer Sci. 2018; 110(1):345-355. PMC: 6317944. DOI: 10.1111/cas.13843. View

17.

Kiyohara Y, Yoshino K, Kubota S, Okuyama H, Endo H, Ueda Y . Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer. Cancer Sci. 2016; 107(4):452-60. PMC: 4832863. DOI: 10.1111/cas.12898. View

18.

DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C . A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43(5):491-8. PMC: 3083463. DOI: 10.1038/ng.806. View

19.

Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M . In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS One. 2017; 12(3):e0174151. PMC: 5354432. DOI: 10.1371/journal.pone.0174151. View

20.

Shoemaker R . The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6(10):813-23. DOI: 10.1038/nrc1951. View